DNA
NEW YORK, July 11 (Reuters) - Genentech Inc. (DNA.N: Quote, Profile, Research) , coming off a run of recent clinical successes, on Monday reported quarterly profit rose on strong sales of its cancer treatments.
The world's second-largest biotechnology company said it now expects 2005 earnings growth, excluding items, of at least 35 percent over 2004 levels.
Genentech posted a second-quarter profit of $296.2 million, or 27 cents per share, compared with a profit of $170.8 million, or 16 cents, a year ago.
The world's second-largest biotechnology company said it now expects 2005 earnings growth, excluding items, of at least 35 percent over 2004 levels.
Genentech posted a second-quarter profit of $296.2 million, or 27 cents per share, compared with a profit of $170.8 million, or 16 cents, a year ago.
0 Comments:
Post a Comment
<< Home